ERBB2 and neoplasm: They observed 92% (23 of 25) PLAUR gene amplification in HER2 amplified cases in touch preps of primary tumor and CTCs; whereas in HER2 nonamplified tumors, only 3% (1 of 39) were PLAUR gene amplified, highlighting the correlation of HER2 and PLAUR gene status.